Domperidone

證據等級: L5

預測適應症: 10 個

Domperidone: From Nausea and Vomiting to Headache Disorder

One-Sentence Summary

Domperidone is a peripheral dopamine D2 receptor antagonist and prokinetic agent, widely used in clinical practice for nausea, vomiting, and gastroparesis management. The TxGNN model predicts it may be effective for Headache Disorder (migraine and related conditions), with 0 registered clinical trials but 20 published literature references currently supporting this direction. Of the 10 predicted indications evaluated, headache disorder carries the strongest evidence base and the only actionable clinical recommendation.

Quick Overview

Item	Content
Original Indication	Antiemetic and upper gastrointestinal prokinetic agent (nausea and vomiting) — no TGA-registered products identified
Predicted New Indication	Headache Disorder (Migraine)
TxGNN Prediction Score	96.72%
Evidence Level	L3
Australia Market Status	Not listed on ARTG
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Domperidone is a selective peripheral dopamine D2 receptor antagonist. Unlike metoclopramide, it does not readily cross the blood–brain barrier and exerts its primary effects at the chemoreceptor trigger zone (area postrema) and peripheral gastrointestinal dopamine receptors. This peripheral selectivity is clinically important: it provides antiemetic and prokinetic benefit with a reduced risk of extrapyramidal side effects. Detailed mechanism of action data from DrugBank was not available for this assessment; however, the drug’s pharmacological profile is well-characterised in the published literature cited below.

The link between domperidone and headache disorders is mechanistically plausible. Migraine pathophysiology involves dopaminergic dysregulation, particularly during the premonitory (prodromal) phase — the period before headache onset characterised by yawning, nausea, photophobia, and fatigue. D2 receptor hypersensitivity is thought to drive these premonitory symptoms, and domperidone’s peripheral D2 blockade may interrupt this early dopaminergic cascade. Importantly, some evidence suggests that treating the premonitory phase — rather than waiting for headache onset — may prevent or attenuate the full attack. Domperidone has also been studied specifically as an adjunct antiemetic during dihydroergotamine (DHE) infusion protocols for intractable migraine.

A further mechanistic rationale relates to pharmacokinetics during attacks: migraine induces gastroparesis, slowing gastric emptying and impairing oral drug absorption. Domperidone’s prokinetic action restores gastric motility, enhancing the bioavailability of co-administered analgesics and triptans. This prokinetic-antiemetic synergy is recognised in multiple international guidelines, including the Canadian Headache Society guidelines, and has been directly tested in a randomised comparison of a domperidone–paracetamol fixed combination (Domperamol) versus sumatriptan 50 mg. While domperidone is not currently TGA-registered in Australia, this evidence base provides solid biological and clinical justification for repurposing evaluation.

Clinical Trial Evidence

Currently no related clinical trials are registered for Domperidone in headache disorder on ClinicalTrials.gov or the ICTRP.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
11191009	2000	RCT	Current Medical Research and Opinion	Randomised UK primary care study (n=120) comparing Domperamol (domperidone + paracetamol) with sumatriptan 50 mg in moderate-to-severe migraine; assessed effectiveness, tolerability and cost
27837002	2016	Prospective Safety Study	Neurology	Evaluated domperidone safety for nausea associated with dihydroergotamine (DHE) infusion for refractory headache; defined cardiac monitoring requirements
33409110	2020	Prospective Observational	Cureus	Real-life tertiary care study of headache clinical profiles and management patterns; domperidone included in treatment regimens; MIDAS and HIT-6 disability assessments used
23968886	2013	Clinical Guideline	Canadian Journal of Neurological Sciences	Canadian Headache Society acute migraine guideline; prokinetic antiemetics including domperidone included in evidence-based management algorithms for episodic migraine
25877672	2015	Clinical Review	Headache	Systematic review of acute migraine treatment options in adults; covers role of prokinetics including domperidone for nausea control and absorption enhancement of NSAIDs and triptans
38822165	2024	Review	CNS Drugs	Reviews pharmacotherapy targeting the migraine premonitory phase; discusses dopaminergic interventions including domperidone as candidates for attack prevention before headache onset
12463273	2001	Review	Current Medical Research and Opinion	Antiemetics in migraine: metoclopramide and domperidone highlighted for prokinetic effect overcoming gastric stasis and improving analgesic absorption
10494007	1999	Review	Canadian Journal of Clinical Pharmacology	Domperidone and metoclopramide shown to improve gastrointestinal absorption of analgesics and triptans during migraine; role in managing nausea-dominant presentations
9876882	1998	Review	Cephalalgia	Reviews pathophysiology and pharmacology of emesis in migraine; dopamine D2 receptor antagonism by domperidone contextualised within acute and future migraine treatment strategies
8749241	1995	Review	Cephalalgia	Domperidone 20 mg orally recommended as antiemetic in combination with analgesics or ergot alkaloids for migraine; early introduction advised; mechanism of improving drug resorption discussed

Australia Market Information

Domperidone is not currently registered on the Australian Register of Therapeutic Goods (ARTG). No TGA-approved products were identified. Clinicians wishing to use domperidone in Australia would need to access it via the TGA Special Access Scheme (SAS) (Category B or C) or apply for Authorised Prescriber status through the TGA.

Domperidone is registered and available in comparable markets including the United Kingdom (MHRA), Canada (Health Canada), and the European Union (EMA), where it is approved for nausea and vomiting. The EMA conducted a benefit–risk review in 2014 and issued restrictions on dose and duration due to cardiac safety concerns.

Safety Considerations

Domperidone does not have a TGA-approved Product Information document as it is not registered in Australia. Based on international regulatory assessments and evidence identified in this pack, clinicians should be aware of the following key safety issues:

QT Prolongation and Cardiac Risk: Domperidone is associated with dose-dependent QT interval prolongation and an increased risk of serious ventricular arrhythmia, including Torsades de Pointes and sudden cardiac death. The EMA (2014) restricted use to the lowest effective dose (10 mg up to three times daily orally) for the shortest possible duration. A case report in this evidence pack (PMID 34530950) describes a young patient who developed concurrent Kounis syndrome (allergic acute coronary syndrome) and prolonged QTc associated with domperidone exposure — an important adverse signal.
Drug Interactions: Concomitant use with other QT-prolonging drugs (e.g., antifungal azoles such as ketoconazole, macrolide antibiotics, antipsychotics, antiarrhythmics) is contraindicated. Domperidone is a CYP3A4 substrate; inhibitors of CYP3A4 significantly increase plasma domperidone concentrations and QT risk.
Cardiac Risk Factors: Use requires caution or avoidance in patients with pre-existing cardiac disease, electrolyte disturbances (hypokalaemia, hypomagnesaemia), or those on other QT-prolonging medications. Baseline ECG is recommended before initiation.
Prolactin Elevation: Long-term use may cause hyperprolactinaemia, which can lead to galactorrhoea, gynaecomastia, and menstrual irregularities.

Please refer to the MHRA/EMA Product Information and TGA’s SAS prescribing guidance for comprehensive safety and contraindication details.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple published literature references — including a direct randomised comparison of domperidone+paracetamol versus sumatriptan, prospective safety data with DHE, and endorsement in international clinical guidelines — establish a clinically plausible and practically relevant role for domperidone in headache disorder management. The evidence reaches Level L3 (observational studies, systematic reviews, and guidelines), which is insufficient for formal indication approval but sufficient to justify structured clinical evaluation.

To proceed, the following is needed:

Regulatory pathway: TGA Special Access Scheme (SAS Category B/C) or Authorised Prescriber application, as domperidone has no current ARTG registration
Cardiac safety protocol: Mandatory baseline ECG, electrolyte screening, and a structured cardiac monitoring plan prior to use; contraindication checklist for QT-prolonging comedications
MOA documentation: Retrieve full DrugBank mechanism of action data (DB01184) to formalise the dopamine–migraine mechanistic rationale for any regulatory or ethics submission
Dose and duration governance: Adhere to EMA-recommended restrictions (≤10 mg three times daily orally, shortest effective duration) given cardiac risk profile
Clinical evidence gap: No registered clinical trials exist for this indication; a prospective observational registry or Phase 2 pilot RCT in Australian migraine patients would substantially strengthen the evidence base to reach L2
Special populations assessment: Evaluate safety in elderly patients and those with pre-existing cardiac conditions, who are at disproportionately higher risk of QT-related events

Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before therapeutic application. All information should be interpreted in conjunction with current TGA guidelines and the prescribing clinician’s professional judgement.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.